SCIEX competitors

Mike McMullen is Agilent’s CEO-elect. He will assume the CEO position in March 2015 when William (Bill) Sullivan takes an advisory role until his retirement. As a first step in the CEO transition, McMullen has been named president and chief operating officer. McMullen has more than 30 years of industry experience and senior management experience at Agilent. He has been president of the company’s Chemical Analysis Group (CAG) since 2009, a role he still fills on an acting basis. As head of CAG, McMullen transformed the business, consistently delivering market-leading growth and profits. He championed strategic acquisitions and architected Agilent’s China strategy. He built the Agilent-wide Services business that has now been made one of Agilent’s three major businesses. McMullen has extensive experience working across Agilent’s businesses, and is recognized for his inspirational leadership style. He also has significant international experience, having lived in Japan, leading Agilent’s Japan field sales and support operations, and later adding responsibility for China field operations. McMullen joined Agilent’s predecessor, Hewlett-Packard Co., in 1984 as a financial analyst. He holds a bachelor's degree in economics and business administration from the University of Delaware and an MBA from Wharton Business School.

Jim Green is Chairman, President and CEO of Harvard Bioscience (NASDAQ: HBIO). With a tract record of successful turn-a-rounds Green was named operating President and CEO in July 2019 by the Board and tasked to create substantial shareholder value through the fundamentals by turning the company into a profitable growth oriented platform. Green served as President and CEO of Analogic Corporation (NASDAQ: ALOG) from 2007 to 2016. While leading Analogic through the great recession, Analogic’s core revenues grew over 50%, and gross margins, operating margins and earnings per share dramatically improved. Immediately prior to becoming President and CEO of Harvard Bioscience, Green served as President of Spacelabs Healthcare, where he led a successful global restructuring, rationalizing the company’s cost structure and product portfolio and quickly stabilized the business, with revenues returning to organic growth while significantly improving gross and operating margins with operating profit improving over 50%.

Dr. Singh was elected President and Chief Executive Officer of PerkinElmer effective December 30, 2019, and appointed to our board of directors in August 2019. Previously Dr. Singh was the President and Chief Operating Officer of the Company since January 2019. Dr. Singh joined PerkinElmer as the President of our Diagnostics business in May 2014. He was elected Senior Vice President in September 2016 and Executive Vice President in March 2018. Prior to joining PerkinElmer, Dr. Singh was General Manager of GE Healthcare’s Women’s Health business from 2012 to 2014, with responsibility for its mammography and bone densitometry businesses. Before that, Dr. Singh held senior executive level roles in strategy, business development and mergers & acquisitions at both GE Healthcare and Philips Healthcare. Earlier in his career, he held leadership roles of increasing responsibility at DuPont Pharmaceuticals and subsequently Bristol-Myers Squibb Medical Imaging, which included managing the Asia Pacific and Middle East region. Dr. Singh holds a doctoral degree in chemistry from the University of Missouri-Columbia and a Master of Business Administration from Northeastern University. His research work has resulted in several issued patents and publications in peer reviewed journals. Dr. Singh has more than twenty-five years of leadership experience with global innovators in healthcare technology. He has spent the most recent six years developing unique insights into both our business and our opportunities for continued growth. Dr. Singh brings to our board a detailed understanding of the core technologies that we utilize and the operational strategies available to us as we continue to focus on innovating for a healthier world.

Joined Varian as an intern in 1999, then full time in 2001, and has held multiple cross-functional roles and executive positions during two-decade tenure with the company. Intimate understanding of healthcare, software solutions, medical devices, technology trends, reimbursement trends and strategies that lead to success in targeted channel segments globally. Marketing strategy, new product launch, portfolio strategy, M&A, P&L, restructuring, government relations, and general management experience. Consistent creation of strategies and execution against operating plans, sales goals and market objectives, including extensive experience of both high growth and slow growth periods (turnaround plans) of Varian Medical Systems journey from $500M to over $3B. Including returning Varian to double digit growth following becoming President of the $3B+ P&L of Oncology systems. Strong leadership skills with a track record of creating an inspiring vision and communicating effectively both internally/externally through developing cultural, servant leadership and focusing on people/teams to drive net promoter scores to all-time highs and enable sustainable long-term success.

Emmanuel Waters is a Founding Partner at Old Hillside Bourbon Company, Chief Executive Officer at WATERS CORPORATION, and Contracts Consultant at Forward Networks Inc and is based in San Francisco, California. He has worked as Principal Subcontract Administrator at Lawrence Berkeley National Lab, Contract Administrator at Department Of Defense, and Contracts Specialist at INFINERA CORP. Emmanuel attended GRADUATE SCHOOL between 2015 and 2015, Texas A&M University-Commerce between 2017 and 2018, and Defense Acquisition University between 2010 and 2015.